{"code":"Q2053","short_description":"Brexucabtagene car pos t","long_description":"Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose","status":"active","section":"Q-codes: Temporary Codes","category":"Temporary","effective_date":"2021-04-01","termination_date":null,"replacement_code":"","opps_status_indicator":"K","opps_status_label":"Non-pass-through drugs and biologicals","opps_apc":"9391","fee_schedules":[],"mue":[],"drug_classes":[],"ndc_crosswalk":[{"ndc":"71287-0219-01","drug_name":"Tecartus","dosage":"UP TO 200 million autologous anti-CD19 CAR positive viable T cells","unit":"1","labeler_name":"Gilead Sciences, Inc."},{"ndc":"71287-0220-01","drug_name":"Tecartus","dosage":"UP TO 200 million autologous anti-CD19 CAR positive viable T cells","unit":"1","labeler_name":"Gilead Sciences, Inc."}],"utilization":[],"urls":{"self_html":"https:\/\/hcpcslookup.com\/codes\/q2053","self_json":"https:\/\/hcpcslookup.com\/api\/codes\/Q2053.json"}}